Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Sandeep Kumar
 + 1278 word(s) 1278 2022-02-22 07:18:40 |
2 format correction
Peter Tang
 Meta information modification 1278 2022-03-04 04:35:15 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Kumar, S. Mitogen-Activated Protein Kinase Inhibitors and Immunotherapy in Cancer. Encyclopedia. Available online: https://encyclopedia.pub/entry/20181 (accessed on 01 December 2024).
Kumar S. Mitogen-Activated Protein Kinase Inhibitors and Immunotherapy in Cancer. Encyclopedia. Available at: https://encyclopedia.pub/entry/20181. Accessed December 01, 2024.
Kumar, Sandeep. "Mitogen-Activated Protein Kinase Inhibitors and Immunotherapy in Cancer" Encyclopedia, https://encyclopedia.pub/entry/20181 (accessed December 01, 2024).
Kumar, S. (2022, March 03). Mitogen-Activated Protein Kinase Inhibitors and Immunotherapy in Cancer. In Encyclopedia. https://encyclopedia.pub/entry/20181
Kumar, Sandeep. "Mitogen-Activated Protein Kinase Inhibitors and Immunotherapy in Cancer." Encyclopedia. Web. 03 March, 2022.
Mitogen-Activated Protein Kinase Inhibitors and Immunotherapy in Cancer
Edit
This entry is adapted from the peer-reviewed paper 10.3390/ph13010009

Mitogen-activated protein kinase (MAPK) signaling networks serve to regulate a wide range of physiologic and cancer-associated cell processes. For instance, a variety of oncogenic mutations often lead to hyperactivation of MAPK signaling, thereby enhancing tumor cell proliferation and disease progression. As such, several components of the MAPK signaling network have been proposed as viable targets for cancer therapy.

cancer mitogen-activated protein kinase T cells Programmed cell death protein 1 Programmed death-ligand 1 cytotoxic T-lymphocyte-associated protein 4 T-cell anergy immunotherapy

1. Introduction

Mitogen-activated protein kinase (MAPK) signaling is mediated by several MAPK family members, sharing several evolutionary-conserved domains [1]. Together, these events are contributing to a wide range of cellular function including proliferation [2], migration [3], angiogenesis [4], invasion [5], metastasis [6] and apoptosis [7]. Classically, MAPK signals are activated downstream of receptor tyrosine kinases, including epithelial growth factor receptor (EGFR) [8]. However, in cancer, MAPK signaling is commonly hyperactivated due to gain of function mutations in proto-oncogenes including B-Raf proto-oncogene, serine/threonine kinase (B-Raf) [9], neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) [10], Kirsten rat sarcoma viral oncogene homolog (KRAS) [11], Raf-1 proto-oncogene, serine/threonine kinase (RAF1) [12], or loss of function mutations to negative regulators including neurofibromatosis type 1 (NF1), in each case leading to enhanced cell proliferation and survival [13].
Previous reports suggest that MAPK signaling is essential for T-cell development [14], activation [15], proliferation and survival [16]. Unsurprisingly, MAPK signaling is also implicated in directing interactions between tumor cells and the surrounding T-cell infiltrate, though these roles are complex and often contradictory. For instance, MAPK signaling has been shown to suppress the expression of negative immune checkpoints such as programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) in several cancers [17]. Similarly, various MAPK members down regulate T-cell costimulatory molecules such as tumor necrosis factor receptor superfamily, member 4 (TNFRSF4), also known as CD134 or OX40 and tumor necrosis factor receptor superfamily member 9 (TNFRSF9) also known as CD137 or 4-1BB, thereby impeding T-cell activation and effector function [18].

2. MEK/ERK Inhibition

ERK was the first MAPK family member to be cloned and characterized [19], and is most commonly activated by the upstream RAS/RAF/MEK cascade [20]. ERK signaling regulates a variety of benign and malignant cell functions, including proliferation, differentiation, motility, and survival [21]. While the role of ERK signaling is well described in tumor cells, ERK is also crucial in the regulation of several aspects of T-cell biology, including positive/negative selection in the thymus [22]. In mature T-cells, ERK is activated following interaction between the T-cell receptor (TCR) and major histocompatibility complex (MHC) on an antigen-presenting cell [23], where it functions to direct the activation of a T cell [24] as well as interleukin-2 (IL-2) production and clonal expansion [25]. This is particularly true with respect to effector CD8+ T-cells, which are dependent on ERK signaling to remain functionally active [26].
Several selective inhibitors of ERK signaling are reported to have marked antitumor efficacy, including FR180204 [27], BVD523 [28], CC90003 [29], GDC-0994 [30] and MK-8353 [31]. BVD523 (Ulixertinib) specifically has been used in clinical trials, showing clear efficacy in patients who have been previously treated with immunotherapy [28].
Mitogen-activated protein kinase kinase (MEK, also known as MAP2K) is an upstream MAPK kinase family member that phosphorylates MAPK members ERK, p38 and JNK [32], though MEK is most clearly associated with ERK activation [33]. Accordingly, MEK/ERK has also been proposed as a potential target for therapy (Table 1).
Table 1. MEK/ERK inhibitors and immunotherapy in cancer.

MEK/ERK Member

Inhibitor

Combination with Immunotherapy

Cancer Type

MEK1/2

Trametinib

4-1BB and OX40 agonist antibodies

Breast cancer [18]

Selumetinib

Anti-EGFR antibody

Lung adenocarcinoma [34]

G-38963

Anti-PD-L1 antibody

Colon carcinoma [35]

ERK1/2

BVD523

Positive outcomes in patients previously treated with immunotherapy

NRAS-, BRAF V600–, and non–V600 BRAF-mutant solid tumors [28]

3. JNK Inhibition

JNK proteins are also MAPK family members and were first discovered in the 1990s [36]. JNK signals are activated by several upstream MAPK members [37] as well as G-protein-coupled receptors (GPCRs) [38]. Like other MAPKs, JNK signaling pathways regulate several cellular functions [39]. Accordingly, JNK signals also appear to regulate T-cell differentiation and function [40], though the contributions of JNK signaling are re-multifaceted and context-dependent. For example, when thymocytes undergo apoptosis, JNK2 targets Jun proto-oncogene (c-JUN) to promote cell death, whereas during proliferation, JNK2 targets nuclear factor of activated T-cells (NFAT) to mediate DNA binding [41]. Further, JNK cooperates with MEKK2 signaling to direct IL-2 biosynthesis, serving crucial roles in TCR/CD3-mediated T-cell signaling [42]. Interestingly, JNK appears to differentially regulate CD4+ and CD8+ T-cell function [43].
However, there are several emerging JNK inhibitors, including SP600125 [44], AS601245 [45], CC-401 [46], AS602801 [47], D-JNKI-1 [48] and BI-78D3 [49], that are now showing early efficacy in various solid tumor types [50]. Interestingly, the JNK inhibitor SP600125 has been suggested to rescue cytotoxic T-lymphocytes from activation-induced cell death without diminishing their capacity to synthesize cytotoxic cytokines such as IFNγ [51]. Hence, while JNK is not yet substantiated as a viable target for combined immunotherapies, it warrants future consideration in combination with immune checkpoint inhibitors.

4. p38 MAPK Inhibition

The p38, another MAPK family member, also appears to have important roles in immune function. The p38 MAPK is activated by environmental stress as well as several inflammatory cytokines [52]. Like other MAPKs, the functions of p38 have been well-established in tumor cells, directing any number of cell processes including differentiation, migration, and inflammation [53]. Accordingly, p38 overexpression is associated with poor responses to conventional therapy in several cancers including breast cancer, nasopharyngeal carcinoma, gastric, and pancreatic cancer [54][55][56][57].
To date, a number of selective inhibitors of p38 MAPK have been synthesized including SCIO-469 [58], BIRB-796 [59], LY2228820 [60], VX-745 [61], SB203580 [62] and PH-797804 [63]. Several are beginning to show early efficacy in cervical [64], pancreatic, ovarian, [65] and breast cancers [60]. Additionally, p38 MAPK inhibition cooperated with anti-CD137 to promote antitumor T-cell responses in glioblastoma [66]. Further, p38 inhibition appears to increase the expression of OX40L and downstream OX40 signaling in dendritic cells (DCs), thereby potentiating effector T-cell function [67]. Hence, while the clinical utility of p38 inhibition also remains unclear, p38 inhibitors also warrant exploration in the setting of immune checkpoint inhibition.

5. Other MAPK Family Members

Several nonclassic MAPK family members also appear to have paramount roles in T-cell biology, and their inhibition may also warrant consideration as an adjuvant to immunotherapy. For example, Hematopoietic Progenitor Kinase-1 (HPK1) is a member of the MAP4K family expressed largely in hematopoietic cells [68], and acts upstream of MAPK signaling [69]. HPK1 has been reported to regulate both nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) and activates JNK signaling pathway [70], and is associated with progression of gastrointestinal tumors [71]. The roles of HPK1 in T-cell function is now becoming clear.
Another upstream regulator of MAPK signaling, germinal center-like kinase (GLK or MAP4K3) belongs to serine/threonine-protein kinase, Ste20 family of protein kinases [72], and may also have important roles in T-cell function. GLK is activated by stimuli including ultraviolet radiation and several proinflammatory cytokines [72], and has clear roles in the pathogenesis of both autoimmune disease and cancer [73]. Clinically, GLK overexpression predicts poor overall and progression-free survival in non-small-cell lung carcinoma (NSCLC) [74], though the mechanisms through which GLK contributes to disease pathogenesis are not clear at this time. However, emerging evidence suggests that GLK regulates T-cell activation via IL-17A signaling [75]. Accordingly, the GLK inhibitor, Verteporfin, has been approved by FDA in macular degeneration of eyes [76] and may warrant exploration in cancer.

Mixed lineage kinases (MLKs) are member of MAP3K family that contain serine/threonine and tyrosine kinase activities [77][78]. Recently, a member of MLK family, MLK3 has been reported to be involved in regulation of T cell activation and cytotoxicity [79]. Furthermore, it has also been reported that genetic loss or pharmacological inhibition of MLK3 induces CD70-mediated apoptosis in CD8+ T cells [80]. Considering this fact a rationalized combination of MLK3 and CD70 antagonists showed anticancer efficacy in triple-negative breast cancer pre-clinical model [80]. Further studies are required to explore role of several MAPKs upstream regulators in cancer and immunotherapy.

References

  1. Schaeffer, H.J.; Weber, M.J. Mitogen-activated protein kinases: Specific messages from ubiquitous messengers. Mol. Cell. Biol. 1999, 19, 2435–2444.
  2. Zhang, W.; Liu, H.T. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002, 12, 9–18.
  3. Huang, C.; Jacobson, K.; Schaller, M.D. MAP kinases and cell migration. J. Cell Sci. 2004, 117, 4619–4628.
  4. Sohn, S.J.; Sarvis, B.K.; Cado, D.; Winoto, A. ERK5 MAPK regulates embryonic angiogenesis and acts as a hypoxia-sensitive repressor of vascular endothelial growth factor expression. J. Biol. Chem. 2002, 277, 43344–43351.
  5. Krueger, J.S.; Keshamouni, V.G.; Atanaskova, N.; Reddy, K.B. Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion. Oncogene 2001, 20, 4209–4218.
  6. Hickson, J.A.; Huo, D.Z.; Vander Griend, D.J.; Lin, A.N.; Rinker-Schaeffer, C.W.; Yamada, S.D. The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res. 2006, 66, 2264–2270.
  7. Wada, T.; Penninger, J.M. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004, 23, 2838–2849.
  8. Wee, P.; Wang, Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers 2017, 9, 52.
  9. Amaral, T.; Sinnberg, T.; Meier, F.; Krepler, C.; Levesque, M.; Niessner, H.; Garbe, C. The mitogen-activated protein kinase pathway in melanoma part I—Activation and primary resistance mechanisms to BRAF inhibition. Eur. J. Cancer 2017, 73, 85–92.
  10. Ellerhorst, J.A.; Ekmekcioglu, S.; Johnson, M.K.; Cooke, C.P.; Johnson, M.M.; Grimm, E.A. Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma. Oncogene 2006, 25, 3956–3962.
  11. Nan, X.; Tamguney, T.M.; Collisson, E.A.; Lin, L.J.; Pitt, C.; Galeas, J.; Lewis, S.; Gray, J.W.; McCormick, F.; Chu, S. Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway. Proc. Natl. Acad. Sci. USA 2015, 112, 7996–8001.
  12. Schonwasser, D.C.; Marais, R.M.; Marshall, C.J.; Parker, P.J. Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol. Cell. Biol. 1998, 18, 790–798.
  13. Plotnikov, A.; Zehorai, E.; Procaccia, S.; Seger, R. The MAPK cascades: Signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim. Biophys. Acta 2011, 1813, 1619–1633.
  14. Lapinski, P.E.; King, P.D. Regulation of Ras signal transduction during T cell development and activation. Am. J. Clin. Exp. Immunol. 2012, 1, 147–153.
  15. Schafer, P.H.; Wang, L.; Wadsworth, S.A.; Davis, J.E.; Siekierka, J.J. T cell activation signals up-regulate p38 mitogen-activated protein kinase activity and induce TNF-alpha production in a manner distinct from LPS activation of monocytes. J. Immunol. 1999, 162, 659–668.
  16. D’Souza, W.N.; Chang, C.F.; Fischer, A.M.; Li, M.; Hedrick, S.M. The Erk2 MAPK regulates CD8 T cell proliferation and survival. J. Immunol. 2008, 181, 7617–7629.
  17. Atsaves, V.; Leventaki, V.; Rassidakis, G.Z.; Claret, F.X. AP-1 transcription factors as regulators of immune responses in cancer. Cancers 2019, 11, 1037.
  18. Dushyanthen, S.; Teo, Z.L.; Caramia, F.; Savas, P.; Mintoff, C.P.; Virassamy, B.; Henderson, M.A.; Luen, S.J.; Mansour, M.; Kershaw, M.H.; et al. Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer. Nat. Commun. 2017, 8, 606.
  19. Boulton, T.G.; Nye, S.H.; Robbins, D.J.; Ip, N.Y.; Radziejewska, E.; Morgenbesser, S.D.; Depinho, R.A.; Panayotatos, N.; Cobb, M.H.; Yancopoulos, G.D. Erks—A family of protein-serine threonine kinases that are activated and tyrosine phosphorylated in response to insulin and Ngf. Cell 1991, 65, 663–675.
  20. Li, L.; Zhao, G.D.; Shi, Z.; Qi, L.L.; Zhou, L.Y.; Fu, Z.X. The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC. Oncol. Lett. 2016, 12, 3045–3050.
  21. Yujiri, T.; Sather, S.; Fanger, G.R.; Johnson, G.L. Role of MEKK1 in cell survival and activation of JNK and ERK pathways defined by targeted gene disruption. Science 1998, 282, 1911–1914.
  22. Fischer, A.M.; Katayama, C.D.; Pages, G.; Pouyssegur, J.; Hedrick, S.M. The role of erk1 and erk2 in multiple stages of T cell development. Immunity 2005, 23, 431–443.
  23. Lafont, V.; Ottones, F.; Liautard, J.; Favero, J. Evidence for a p21 (ras)/Raf-1/MEK-1/ERK-2-independent pathway in stimulation of IL-2 gene transcription in human primary T lymphocytes. J. Biol. Chem. 1999, 274, 25743–25748.
  24. Nekrasova, T.; Shive, C.; Gao, Y.H.; Kawamura, K.; Guardia, R.; Landreth, G.; Forsthuber, T.G. ERK1-deficient mice show normal T cell effector function and are highly susceptible to experimental autoimmune encephalomyelitis. J. Immunol. 2005, 175, 2374–2380.
  25. Dillon, T.J.; Carey, K.D.; Wetzel, S.A.; Parker, D.C.; Stork, P.J. Regulation of the small GTPase Rap1 and extracellular signal-regulated kinases by the costimulatory molecule CTLA-4. Mol. Cell. Biol. 2005, 25, 4117–4128.
  26. Ohnishi, H.; Takeda, K.; Domenico, J.; Lucas, J.J.; Miyahara, N.; Swasey, C.H.; Dakhama, A.; Gelfand, E.W. Mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2-dependent pathways are essential for CD8(+) T cell-mediated airway hyperresponsiveness and inflammation. J. Allergy Clin. Immun. 2009, 123, 249–257.
  27. Ohori, M.; Kinoshita, T.; Okubo, M.; Sato, K.; Yamazaki, A.; Arakawa, H.; Nishimura, S.; Inamura, N.; Nakajima, H.; Neya, M.; et al. Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. Biochem. Biophys. Res. Commun. 2005, 336, 357–363.
  28. Sullivan, R.J.; Infante, J.R.; Janku, F.; Wong, D.J.L.; Sosman, J.A.; Keedy, V.; Patel, M.R.; Shapiro, G.I.; Mier, J.W.; Tolcher, A.W.; et al. First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: Results of a phase I dose-escalation and expansion study. Cancer Discov. 2018, 8, 184–195.
  29. Aaron, C.P.; Tandri, H.; Barr, R.G.; Johnson, W.C.; Bagiella, E.; Chahal, H.; Jain, A.; Kizer, J.R.; Bertoni, A.G.; Lima, J.A.; et al. Physical activity and right ventricular structure and function: The MESA-right ventricle study. Am. J. Respir. Crit. Care Med. 2011, 183, 396–404.
  30. Kirouac, D.; Schaefer, G.; Chan, J.; Merchant, M.; Orr, C.; Liu, L.; Huang, A.; Moffat, J.; Gadkar, K.; Ramanujan, S. Clinical responses to ERK inhibitor (GDC-0994) treatment combinations predicted using a Quantitative Systems Pharmacology model of MAPK signaling in BRAF(V600E)-mutant colorectal cancer. Eur. J. Cancer 2016, 69, S20.
  31. Moschos, S.J.; Sullivan, R.J.; Hwu, W.J.; Ramanathan, R.K.; Adjei, A.A.; Fong, P.C.; Shapira-Frommer, R.; Tawbi, H.A.; Rubino, J.; Rush, T.S.; et al. Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 2018, 3.
  32. Bavaria, M.N.; Jin, S.; Ray, R.M.; Johnson, L.R. The mechanism by which MEK/ERK regulates JNK and p38 activity in polyamine depleted IEC-6 cells during apoptosis. Apoptosis 2014, 19, 467–479.
  33. Ritt, D.A.; Abreu-Blanco, M.T.; Bindu, L.; Durrant, D.E.; Zhou, M.; Specht, S.I.; Stephen, A.G.; Holderfield, M.; Morrison, D.K. Inhibition of Ras/Raf/MEK/ERK pathway signaling by a stress-induced phospho-regulatory circuit. Mol. Cell 2016, 64, 875–887.
  34. Stutvoet, T.S.; Kol, A.; de Vries, E.G.E.; de Bruyn, M.; Fehrmann, R.S.N.; van Scheltinga, A.G.T.T.; de Jong, S. MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells. J. Pathol. 2019, 249, 52–64.
  35. Ebert, P.J.R.; Cheung, J.; Yang, Y.; McNamara, E.; Hong, R.; Moskalenko, M.; Gould, S.E.; Maecker, H.; Irving, B.A.; Kim, J.M.; et al. MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. Immunity 2016, 44, 609–621.
  36. Davis, R.J. Signal transduction by the JNK group of MAP kinases. Cell 2000, 103, 239–252.
  37. Cargnello, M.; Roux, P.P. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol. Mol. Biol. Rev. 2011, 75, 50–83.
  38. O’Hayre, M.; Degese, M.S.; Gutkind, J.S. Novel insights into G protein and G protein-coupled receptor signaling in cancer. Curr. Opin. Cell Biol. 2014, 27, 126–135.
  39. Seki, E.; Brenner, D.A.; Karin, M. A liver full of JNK: Signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology 2012, 143, 307–320.
  40. Dong, C.; Yang, D.D.; Tournier, C.; Whitmarsh, A.J.; Xu, J.; Davis, R.J.; Flavell, R.A. JNK is required for effector T-cell function but not for T-cell activation. Nature 2000, 405, 91–94.
  41. Behrens, A.; Sabapathy, K.; Graef, I.; Cleary, M.; Crabtree, G.R.; Wagner, E.F. Jun N-terminal kinase 2 modulates thymocyte apoptosis and T cell activation through c-Jun and nuclear factor of activated T cell (NF-AT). Proc. Natl. Acad. Sci. USA 2001, 98, 1769–1774.
  42. Su, B.; Cheng, J.K.; Yang, J.H.; Guo, Z.J. MEKK2 is required for T-cell receptor signals in JNK activation and interleukin-2 gene expression. J. Biol. Chem. 2001, 276, 14784–14790.
  43. Conze, D.; Krahl, T.; Kennedy, N.; Weiss, L.; Lumsden, J.; Hess, P.; Flavell, R.A.; Le Gros, G.; Davis, R.J.; Rincon, M. C-jun NH2-terminal kinase (JNK)1 and JNK2 have distinct roles in CD8(+) T cell activation. J. Exp. Med. 2002, 195, 811–823.
  44. Bennett, B.L.; Sasaki, D.T.; Murray, B.W.; O’Leary, E.C.; Sakata, S.T.; Xu, W.; Leisten, J.C.; Motiwala, A.; Pierce, S.; Satoh, Y.; et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA 2001, 98, 13681–13686.
  45. Zhang, T.; Inesta-Vaquera, F.; Niepel, M.; Zhang, J.; Ficarro, S.B.; Machleidt, T.; Xie, T.; Marto, J.A.; Kim, N.; Sim, T.; et al. Discovery of potent and selective covalent inhibitors of JNK. Chem. Biol. 2012, 19, 140–154.
  46. Ma, F.Y.; Flanc, R.S.; Tesch, G.H.; Han, Y.; Atkins, R.C.; Bennett, B.L.; Friedman, G.C.; Fan, J.H.; Nikolic-Paterson, D.J. A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis. J. Am. Soc. Nephrol. 2007, 18, 472–484.
  47. Okada, M.; Kuramoto, K.; Takeda, H.; Watarai, H.; Sakaki, H.; Seino, S.; Seino, M.; Suzuki, S.; Kitanaka, C. The novel JNK inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo. Oncotarget 2016, 7, 27021–27032.
  48. Zhao, Y.; Spigolon, G.; Bonny, C.; Culman, J.; Vercelli, A.; Herdegen, T. The JNK inhibitor D-JNKI-1 blocks apoptotic JNK signaling in brain mitochondria. Mol. Cell. Neurosci. 2012, 49, 300–310.
  49. Stebbins, J.L.; De, S.K.; Machleidt, T.; Becattini, B.; Vazquez, J.; Kuntzen, C.; Chen, L.H.; Cellitti, J.F.; Riel-Mehan, M.; Emdadi, A.; et al. Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc. Natl. Acad. Sci. USA 2008, 105, 16809–16813.
  50. Bubici, C.; Papa, S. JNK signalling in cancer: In need of new, smarter therapeutic targets. Br. J. Pharmacol. 2014, 171, 24–37.
  51. Mehrotra, S.; Chhabra, A.; Chattopadhyay, S.; Dorsky, D.I.; Chakraborty, N.G.; Mukherji, B. Rescuing melanoma epitope-specific cytolytic T lymphocytes from activation-induced cell death, by SP600125, an inhibitor of JNK: Implications in cancer immunotherapy. J. Immunol. 2004, 173, 6017–6024.
  52. Hu, M.C.; Wang, Y.P.; Mikhail, A.; Qiu, W.R.; Tan, T.H. Murine p38-delta mitogen-activated protein kinase, a developmentally regulated protein kinase that is activated by stress and proinflammatory cytokines. J. Biol. Chem. 1999, 274, 7095–7102.
  53. Cuenda, A.; Rousseau, S. P38 MAP-kinases pathway regulation, function and role in human diseases. Biochim. Biophys. Acta 2007, 1773, 1358–1375.
  54. Donnelly, S.M.; Paplomata, E.; Peake, B.M.; Sanabria, E.; Chen, Z.; Nahta, R. P38 MAPK contributes to resistance and invasiveness of HER2—Overexpressing breast cancer. Curr. Med. Chem. 2014, 21, 501–510.
  55. Farhat, F.; Daulay, E.R.; Chrestella, J.; Asnir, R.A.; Yudhistira, A.; Susilo, R.R. Correlation of P38 mitogen-activated protein kinase expression to clinical stage in nasopharyngeal carcinoma. Open Access Maced. J. Med. Sci. 2018, 6, 1982–1985.
  56. Guo, X.L.; Ma, N.N.; Wang, J.; Song, J.R.; Bu, X.X.; Cheng, Y.; Sun, K.; Xiong, H.Y.; Jiang, G.C.; Zhang, B.H.; et al. Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells. BMC Cancer 2008, 8.
  57. Zhong, Y.; Naito, Y.; Cope, L.; Naranjo-Suarez, S.; Saunders, T.; Hong, S.M.; Goggins, M.G.; Herman, J.M.; Wolfgang, C.L.; Iacobuzio-Donahue, C.A. Functional p38 MAPK identified by biomarker profiling of pancreatic cancer restrains growth through JNK inhibition and correlates with improved survival. Clin. Cancer Res. 2014, 20, 6200–6211.
  58. Laufer, S.; Lehmann, F. Investigations of SCIO-469-like compounds for the inhibition of p38 MAP kinase. Bioorg. Med. Chem. Lett. 2009, 19, 1461–1464.
  59. Kuma, Y.; Sabio, G.; Bain, J.; Shpiro, N.; Marquez, R.; Cuenda, A. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J. Biol. Chem. 2005, 280, 19472–19479.
  60. Campbell, R.M.; Anderson, B.D.; Brooks, N.A.; Brooks, H.B.; Chan, E.M.; De Dios, A.; Gilmour, R.; Graff, J.R.; Jambrina, E.; Mader, M.; et al. Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity. Mol. Cancer Ther. 2014, 13, 364–374.
  61. Duffy, J.P.; Harrington, E.M.; Salituro, F.G.; Cochran, J.E.; Green, J.; Gao, H.A.; Bemis, G.W.; Evindar, G.; Galullo, V.P.; Ford, P.J.; et al. The discovery of VX-745: A Novel and selective p38 alpha kinase inhibitor. ACS Med. Chem. Lett. 2011, 2, 758–763.
  62. Barancik, M.; Bohacova, V.; Kvackajova, J.; Hudecova, S.; Krizanova, O.; Breier, A. SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance. Eur. J. Pharm. Sci. 2001, 14, 29–36.
  63. Selness, S.R.; Devraj, R.V.; Devadas, B.; Walker, J.K.; Boehm, T.L.; Durley, R.C.; Shieh, H.; Xing, L.; Rucker, P.V.; Jerome, K.D.; et al. Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase. Bioorg. Med. Chem. Lett. 2011, 21, 4066–4071.
  64. Jin, X.; Mo, Q.; Zhang, Y.; Gao, Y.; Wu, Y.; Li, J.; Hao, X.; Ma, D.; Gao, Q.; Chen, P. The p38 MAPK inhibitor BIRB796 enhances the antitumor effects of VX680 in cervical cancer. Cancer Biol. Ther. 2016, 17, 566–576.
  65. Malm, S.W.; Hanke, N.T.; Gill, A.; Carbajal, L.; Baker, A.F. The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines. J. Exp. Clin. Cancer Res. 2015, 34, 31.
  66. Kuhnol, C.; Herbarth, M.; Foll, J.; Staege, M.S.; Kramm, C. CD137 stimulation and p38 MAPK inhibition improve reactivity in an in vitro model of glioblastoma immunotherapy. Cancer Immunol. Immunother. 2013, 62, 1797–1809.
  67. Lu, Y.; Zhang, M.; Wang, S.; Hong, B.; Wang, Z.; Li, H.; Zheng, Y.; Yang, J.; Davis, R.E.; Qian, J.; et al. P38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression. Nat. Commun. 2014, 5, 4229.
  68. Hu, M.C.; Wang, Y.; Qiu, W.R.; Mikhail, A.; Meyer, C.F.; Tan, T.H. Hematopoietic progenitor kinase-1 (HPK1) stress response signaling pathway activates IkappaB kinases (IKK-alpha/beta) and IKK-beta is a developmentally regulated protein kinase. Oncogene 1999, 18, 5514–5524.
  69. Alzabin, S.; Bhardwaj, N.; Kiefer, F.; Sawasdikosol, S.; Burakoff, S. Hematopoietic progenitor kinase 1 is a negative regulator of dendritic cell activation. J. Immunol. 2009, 182, 6187–6194.
  70. Wang, H.; Song, X.; Logsdon, C.; Zhou, G.; Evans, D.B.; Abbruzzese, J.L.; Hamilton, S.R.; Tan, T.H.; Wang, H. Proteasome-mediated degradation and functions of hematopoietic progenitor kinase 1 in pancreatic cancer. Cancer Res. 2009, 69, 1063–1070.
  71. Wang, J.J.; Song, L.J.; Yang, S.; Zhang, W.J.; Lu, P.W.; Li, S.L.; Li, H.X.; Wang, L.X. HPK1 positive expression associated with longer overall survival in patients with estrogen receptor-positive invasive ductal carcinoma-not otherwise specified. Mol. Med. Rep. 2017, 16, 4634–4642.
  72. Diener, K.; Wang, X.S.; Chen, C.; Meyer, C.F.; Keesler, G.; Zukowski, M.; Tan, T.H.; Yao, Z. Activation of the c-Jun N-terminal kinase pathway by a novel protein kinase related to human germinal center kinase. Proc. Natl. Acad. Sci. USA 1997, 94, 9687–9692.
  73. Chuang, H.C.; Tan, T.H. MAP4K3/GLK in autoimmune disease, cancer and aging. J. Biomed. Sci. 2019, 26, 82.
  74. Hsu, C.P.; Chuang, H.C.; Lee, M.C.; Tsou, H.H.; Lee, L.W.; Li, J.P.; Tan, T.H. GLK/MAP4K3 overexpression associates with recurrence risk for non-small cell lung cancer. Oncotarget 2016, 7, 41748–41757.
  75. Chuang, H.C.; Tsai, C.Y.; Hsueh, C.H.; Tan, T.H. GLK-IKKbeta signaling induces dimerization and translocation of the AhR-RORgammat complex in IL-17A induction and autoimmune disease. Sci. Adv. 2018, 4, eaat5401.
  76. Chuang, H.C.; Chen, Y.M.; Chen, M.H.; Hung, W.T.; Yang, H.Y.; Tseng, Y.H.; Tan, T.H. AhR-ROR-gamma t complex is a therapeutic target for MAP4K3/GLK(high)IL-17A(high) subpopulation of systemic lupus erythematosus. FASEB J. 2019, 33, 11469–11480.
  77. Sandeep Kumar; Sunil Kumar Singh; Basabi Rana; Ajay Rana; The regulatory function of mixed lineage kinase 3 in tumor and host immunity. Pharmacology & Therapeutics 2020, 219, 107704.
  78. Sandeep Kumar; Sunil Kumar Singh; Basabi Rana; Ajay Rana; Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights. Drug Discovery Today 2021, 26, 951-967.
  79. Sandeep Kumar; Sunil Kumar Singh; Navin Viswakarma; Gautam Sondarva; Rakesh Sathish Nair; Periannan Sethupathi; Subhash C. Sinha; Rajyasree Emmadi; Kent Hoskins; Oana Danciu; et al. Mixed lineage kinase 3 inhibition induces T cell activation and cytotoxicity. Proceedings of the National Academy of Sciences 2020, 117, 7961-7970
  80. Sandeep Kumar; Sunil Kumar Singh; Navin Viswakarma; Gautam Sondarva; Rakesh Sathish Nair; Periannan Sethupathi; Matthew Dorman; Subhash C Sinha; Kent Hoskins; Gregory Thatcher; et al. Rationalized inhibition of mixed lineage kinase 3 and CD70 enhances life span and antitumor efficacy of CD8+ T cells. Journal for ImmunoTherapy of Cancer 2020, 8, e000494.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Oncology
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Sandeep Kumar
View Times: 407
Revisions: 2 times (View History)
Update Date: 29 Mar 2022
Table of Contents
    1000/1000
    Hot Most Recent
    ScholarVision Creations
    Feedback